The accurate prognostic prediction of GC are pivotal in clinical practice. At present, as the main method, TNM stage system is widely applied to reveal tumor progression and predict prognosis of patients. Nevertheless, TNM stage can only reflect the general information of tumor progression. Because of the heterogeneity, the individual specific characteristics of tumors and patients cannot be completely revealed only through TNM stage system. With the development of biological technology, the heterogeneity of genetics, like proteomics, genomics, has been gradually discovered in GC . Therefore, besides TNM stage, it is very important to take the heterogeneity of GC into consideration in prognostic prediction. Additionally, CSCs, as the putative source of tumor maintaining and therapy resistance, have also been investigated deeply and widely in many tumors in recent years. In this present study, we focused on the expressions of specific markers of CSCs in GC tissues to find out their clinical significance in GC and potential application in clinical practice.